Abraham Ceesay, Chief Executive Officer at Rapport Therapeutics, Inc. (RAPP), sold 20,717 shares at $30.04 ($612K) on 2025-12-17, disclosed to the SEC on 2025-12-18.
Scheduled sale ($612k) by Chief Executive Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $28.84 | 2,441 | $70K | 11.5% |
| 2 | $28.84 | 2,441 | $70K | 11.5% |
| 3 | $28.84 | 2,147 | $62K | 10.1% |
| 4 | $28.84 | 2,147 | $62K | 10.1% |
| 5 | $30.04 | 2,792 | $84K | 13.7% |
| 6 | $30.04 | 2,421 |
| $73K |
| 11.9% |
| 7 | $30.04 | 2,792 | $84K | 13.7% |
| 8 | $30.04 | 2,421 | $73K | 11.9% |
| 9 | $31.04 | 600 | $19K | 3.0% |
| 10 | $31.04 | 515 | $16K | 2.6% |
| Total | $29.56 avg | 20,717 | $612K | 100% |
| Filing → |
| RAPP | SELL | 2026-08-26 | $938K | — | Filing → |
| RAPP | SELL | 2026-08-12 | $2.4M | — | Filing → |
| RAPP | SELL | 2026-07-29 | $93K | — | Filing → |